NeuroSense Therapeutics
NRSN

$1.35

0%

Market Cap: $26.3M

About: NeuroSense Therapeutics Ltd is a clinical-stage biotechnology company focused on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases, these diseases include Amyotrophic Lateral Sclerosis, or ALS, Alzheimer's disease and Parkinson's disease, among others. Its product candidate, PrimeC, is a novel extended-release, or ER, oral formulation of a fixed dose combination of two generic FDA-approved drugs, ciprofloxacin and celecoxib, combined in a specific ratio.

Employees: 16

0

Funds holding %

of 6,710 funds

–

Analysts bullish %

Fund manager confidence

Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)

510% more capital invested

Capital invested by funds: $307K [Q1] → $1.87M (+$1.56M) [Q2]

8.03% more ownership

Funds ownership: 1.23% [Q1] → 9.26% (+8.03%) [Q2]

13% less funds holding

Funds holding: 8 [Q1] → 7 (-1) [Q2]

33% less first-time investments, than exits

New positions opened: 2 | Existing positions closed: 3

100% less repeat investments, than reductions

Existing positions increased: 0 | Existing positions reduced: 2

See Fund Rankings

Research analyst outlook

We haven’t received any recent analyst ratings for NRSN.

See Analyst Rankings

Financial journalist opinion

NeuroSense Therapeutics Announces Receipt of Nasdaq Minimum Bid Price Notification

CAMBRIDGE, Mass. , Aug. 30, 2024 /PRNewswire/ -- NeuroSense Therapeutics Ltd.

NeuroSense Therapeutics Announces Receipt of Nasdaq Minimum Bid Price Notification

NeuroSense Therapeutics Announces Private Placement with Senior Management Participation at Premium to Market Price

CAMBRIDGE, Mass. , Aug. 7, 2024 /PRNewswire/ -- NeuroSense Therapeutics Ltd.

NeuroSense Therapeutics Announces Private Placement with Senior Management Participation at Premium to Market Price

NeuroSense Therapeutics Announces Positive Biomarker Data from ALS Phase 2b Clinical Trial

12-month data demonstrated regulation of iron levels, which aligns with improved ALS survival and disease mitigation Previous results showed PrimeC slowed disease progression by 36% and improved survival rates, highlighting its potential as a transformative ALS therapy CAMBRIDGE, Mass. , Aug. 1, 2024 /PRNewswire/ -- NeuroSense Therapeutics Ltd.

NeuroSense Therapeutics Announces Positive Biomarker Data from ALS Phase 2b Clinical Trial

NeuroSense's PARADIGM ALS Clinical Trial Demonstrates Up to 73% Improved Complication-Free Survival Following Statistically Significant Slowing of Disease Progression

NeuroSense to submit the 12-month data to FDA to discuss path forward CAMBRIDGE, Mass. , July 9, 2024 /PRNewswire/ -- NeuroSense Therapeutics Ltd.

NeuroSense's PARADIGM ALS Clinical Trial Demonstrates Up to 73% Improved Complication-Free Survival Following Statistically Significant Slowing of Disease Progression

This cheap biotech offers investors a play on ALS if trial data continues to impress

NeuroSense Therapeutics Ltd.'s stock rose 6.5% Tuesday, as analysts cheered data from the biotech's late-stage trial of a treatment for the fatal disease amyotrophic lateral sclerosis, or ALS.

This cheap biotech offers investors a play on ALS if trial data continues to impress

NeuroSense Demonstrates Statistically Significant Efficacy and Survival Benefits in People Living with ALS: The Promising Results from the 12-Month PARADIGM Study Highlight PrimeC's Potential as a Disease Modifying Drug

Disease progression was slowed by 36% (p=0.009) in participants who received PrimeC for 12 months compared to those who initially received a placebo Consistent data across multiple endpoints underscore the potential of PrimeC to redefine the ALS treatment paradigm NeuroSense planning for Phase 3 clinical study in the U.S. and Europe CAMBRIDGE, Mass. , July 1, 2024 /PRNewswire/ -- NeuroSense Therapeutics Ltd.

NeuroSense Demonstrates Statistically Significant Efficacy and Survival Benefits in People Living with ALS: The Promising Results from the 12-Month PARADIGM Study Highlight PrimeC's Potential as a Disease Modifying Drug

NeuroSense Management Provides Corporate Update and First Quarter 2024 Financial Results

Following positive 6-month clinical outcomes from phase 2b (PARADIGM) clinical trial, Company expects additional biomarker and 12-month clinical in the near term CAMBRIDGE, Mass. , June 24, 2024 /PRNewswire/ -- NeuroSense Therapeutics Ltd.

NeuroSense Management Provides Corporate Update and First Quarter 2024 Financial Results

NeuroSense Receives Delisting Notice from Nasdaq and Intends to Appeal

CAMBRIDGE, Mass. , June 21, 2024 /PRNewswire/ -- NeuroSense Therapeutics Ltd.

NeuroSense Receives Delisting Notice from Nasdaq and Intends to Appeal

NeuroSense Vice President of R&D Shiran Zimri, Ph.D. to Participate in the 3rd Annual ALS Drug Development Summit

CAMBRIDGE, Mass. , May 20, 2024 /PRNewswire/ -- NeuroSense Therapeutics Ltd.

NeuroSense Vice President of R&D Shiran Zimri, Ph.D. to Participate in the 3rd Annual ALS Drug Development Summit

NeuroSense Partners with PhaseV to Optimize Upcoming ALS Phase 3 Trial Using Advanced Causal Machine Learning

PhaseV's Causal Machine Learning Predicts High Probability of Success in Multiple ALS Subgroups for NeuroSense's Phase 3 Trial CAMBRIDGE, Mass. , May 14, 2024 /PRNewswire/ -- NeuroSense Therapeutics (Nasdaq: NRSN) ("NeuroSense"), a company developing novel treatments for severe neurodegenerative diseases, today announced that it partnered with PhaseV, a pioneer in causal machine learning (ML) for clinical trial analysis and optimization, with respect to the planned Phase 3 trial of PrimeC as a treatment for amyotrophic lateral sclerosis (ALS).

NeuroSense Partners with PhaseV to Optimize Upcoming ALS Phase 3 Trial Using Advanced Causal Machine Learning

See News Rankings